Iovance Biotherapeutics, Inc. (IOVA)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 13.63 |
| Open | 13.80 |
| Bid | 13.88 x 800 |
| Ask | 13.92 x 700 |
| Day's range | 13.73 - 14.23 |
| 52-week range | 3.21 - 18.33 |
| Volume | |
| Avg. volume | 8,957,826 |
| Market cap | 3.884B |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
- Zacks
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
- Simply Wall St.
With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners
Key Insights Given the large stake in the stock by institutions, Iovance Biotherapeutics' stock price might be...
© 2024 Yahoo. All rights reserved.